Abstract
The coming of age for cancer treatment has experienced exponential growth in the last decade with the addition of immunotherapy as the fourth pillar to the fundamentals of cancer treatment-chemotherapy, surgery, and radiation-taking oncology to an astounding new frontier. In this time, rapid developments in computational biology coupled with immunology have led to the exploration of priming the host immune system through vaccination to prevent and treat certain subsets of cancer such as melanoma and hereditary colorectal cancer. By targeting the immune system through tumor-specific antigens-namely, neoantigens (neoAgs)-the future of cancer prevention may lie within arm's reach by employing neoAg vaccines as an immune-preventive modality for hereditary cancer syndromes like Lynch syndrome. In this review, we discuss the history, current trends, utilization, and future direction of neoAg-based vaccines in the setting of hereditary colorectal cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 146-156 |
| Number of pages | 11 |
| Journal | Clinics in Colon and Rectal Surgery |
| Volume | 37 |
| Issue number | 3 |
| DOIs | |
| State | Published - Apr 10 2024 |
Keywords
- cancer prevention
- cancer vaccine
- hereditary colorectal cancer
- Lynch syndrome
- neoantigen
ASJC Scopus subject areas
- Surgery
- Gastroenterology